2019•The Brown University Psychopharmacology UpdateRequires access

Deutetrabenazine shows long‐term effectiveness for tardive dyskinesia

Author information unavailable

Abstract

Deutetrabenazine, which has been shown to improve symptoms of tardive dyskinesia (TD) in two 12‐week trials, now has demonstrated longer‐term efficacy and safety. The latest results were found in open‐label extensions of the Aim to Reduce Movements in Tardive Dyskinesia (ARM‐TD) and Addressing Involuntary Movements in Tardive Dyskinesia (AIM‐TD) trials.

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Tardive dyskinesia, Dyskinesia, Medicine, Term (time), Physical medicine and rehabilitation, Psychiatry, Schizophrenia (object-oriented programming), Internal medicine